A study found that treatment with ticagrelor alone, rather than in combination with aspirin, led to a lower rate of clinically relevant bleeding in patients with acute coronary syndrome who underwent percutaneous coronary intervention. The study involved adults who remained event-free for one month on dual antiplatelet therapy after their procedure. Participants were randomly assigned to receive ticagrelor plus aspirin or ticagrelor plus a placebo. Results showed that ticagrelor monotherapy decreased the risk of bleeding events while providing similar protection from major adverse cardiovascular or cerebrovascular events compared to ticagrelor plus aspirin. This study was published in The Lancet and presented at the American College of Cardiology meeting.
Source link
Ticagrelor monotherapy cuts bleeding risk in acute coronary syndrome
